BRIEF — Chinese I-O company raises another $35 million

Elpiscience Biopharmaceuticals has raised $35 million in a Series A+ financing for its work developing immuno-oncology treatments.

Beijing-based Hillhouse Capital led the round, with CDH Investments and existing investor Lilly Ventures also taking part in the round.

Shanghai-based Elpiscience raised $20 million in its Series A fundraiser last year.